Catalent

Tampa, FL
Find alternatives to Catalent for Monoclonal Antibody →
Monoclonal Antibody Recombinant Protein ADC AAV mRNA Plasmid DNA Fill-Finish
Program data pending ClinicalTrials.gov matching · Last scored 2026-11-12
76.2
Signal Score
✓ FDA Inspections (25) ○ Clinical Trials ○ SEC Filings ✓ Press (20) ✓ EMA GMP (21) ✓ MHRA GMP (18) ✓ HC GMP (76)

Quick Facts: Catalent

Signal Score
76.2/100 (as of 2026-11-12)
Quality Compliance
77.5/100 — OAI classification at Bloomington (2025-07-14) — CRITICAL
Headquarters
Tampa, FL
Website
Modalities
Monoclonal Antibody, Recombinant Protein, ADC, AAV, mRNA, Plasmid DNA, Fill-Finish
Active Programs
No ClinicalTrials.gov matches confirmed — 11 partnership signals in press (announcements, not verified)
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Catalent

Acquired by Novo Holdings for $16.5B.

Signal Score & Pillar Breakdown

Quality Compliance 77.5
OAI classification at Bloomington (2025-07-14) — CRITICAL
OAI classification at Bloomington (2026-04-24) — CRITICAL
Warning Letter: CGMP/Finished Pharmaceuticals/Adulterated
Clean EMA record: 21 active GMP certificates (no deductions)
Clean MHRA record: 18 compliant GMP certificates (no deductions)
Sources: FDA Data Dashboard, EMA EudraGMDP, MHRA GMDP
OAI classification at Bloomington (2025-07-14) — CRITICAL · OAI classification at Bloomington (2026-04-24) — CRITICAL · Warning Letter: CGMP/Finished Pharmaceuticals/Adulterated · Clean EMA record: 21 active GMP certificates (no deductions) · Clean MHRA record: 18 compliant GMP certificates (no deductions)
FDA Inspections25 on record
Warning Letters1
Last InspectionVoluntary Action Indicated (VAI) (2026-05-22)
2025-11-20CGMP/Finished Pharmaceuticals/AdulteratedInspection 2025-06-23 to 2025-07-14, per the letter; letter signed 129 days after it ended.Addressed to Novo Nordisk, which acquired the Bloomington, Indiana site (FEI 3005949964). FDA warning letter
EMA GMP Certificates21 on record
MHRA GMP Certificates18 on record
Most Recent HC OutcomeCompliant · 2025-10-20
HC Attribution76 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
OAI classification at Bloomington (2025-07-14) — CRITICAL
OAI classification at Bloomington (2026-04-24) — CRITICAL
Warning Letter: CGMP/Finished Pharmaceuticals/Adulterated
Clean EMA record: 21 active GMP certificates (no deductions)
Clean MHRA record: 18 compliant GMP certificates (no deductions)
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer. 11 partnership announcements found in press monitoring.
Programs — no verified data
Sponsors— no verified data
ModalitiesMonoclonal Antibody, Recombinant Protein, ADC, AAV, mRNA, Plasmid DNA, Fill-Finish
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability 75.0
Strong parent backing: Novo Holdings (acquired Feb 2024, $16.5B)
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Strong parent backing: Novo Holdings (acquired Feb 2024, $16.5B)
Capacity 75.0
Multi-site operations (14 manufacturing sites)
Broad modality coverage (7 modalities)
Sites: Harmans, MD, Gosselies, Belgium, Limoges, France, Baltimore, MD, Philadelphia, PA, Malvern, PA, Greenville, NC, Morrisville, NC, Winchester, KY, Swindon, United Kingdom, Dartford, United Kingdom, Schorndorf, Germany, Eberbach, Germany, Aprilia, Italy
Source: company profiles (manufacturing sites, modality breadth)
14 manufacturing sites
Press Signals20 articles (not scored)
Multi-site operations (14 manufacturing sites)
Broad modality coverage (7 modalities)

Catalent FDA Inspection History

2026-05
2026-04
2025-12
2025-10
2025-07
2025-06
2025-06
2025-04
2025-04
2024-11
2024-10
2024-05
2024-05
2024-01
2023-11
2023-06
2023-03
2023-01
2023-01
2022-12
2022-09
2022-06
2022-03
2021-11
2026-01
NAI VAI OAI
Date Site Type 483 citations posted Classification
2026-05-22
Catalent Pharma Solutions LLC
Morrisville, North Carolina Facility-linked
Drug Quality Assurance Yes Voluntary Action Indicated (VAI)
2026-04-24
Catalent Indiana, LLC
Bloomington, Indiana Facility-linked
Drug Quality Assurance Not posted Official Action Indicated (OAI)
2025-12-17
Catalent Pharma Solutions, LLC
Philadelphia, Pennsylvania Company-level
Human Cellular, Tissue, and Gene Therapies Not posted No Action Indicated (NAI)
2025-10-24
Catalent Greenville Inc
Greenville, North Carolina Facility-linked
Drug Quality Assurance Yes Voluntary Action Indicated (VAI)
2025-07-14
Catalent Indiana, LLC
Bloomington, Indiana Facility-linked
Drug Quality Assurance Not posted Official Action Indicated (OAI)
2025-06-09
Catalent Micron Technologies, Inc.
Malvern, Pennsylvania Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2025-06-05
Catalent Pharma Solutions, LLC
Philadelphia, Pennsylvania Company-level
Drug Quality Assurance Not posted No Action Indicated (NAI)
2025-04-22
Catalent Pharma Solutions, LLC
Winchester, Kentucky Company-level
Drug Quality Assurance Yes Voluntary Action Indicated (VAI)
2025-04-09
Catalent Maryland, Inc.
Baltimore, Maryland Facility-linked
Human Cellular, Tissue, and Gene Therapies Yes Voluntary Action Indicated (VAI)
2024-11-15
Catalent Maryland Inc
Harmans, Maryland Facility-linked
Human Cellular, Tissue, and Gene Therapies Not posted No Action Indicated (NAI)
2024-10-10
Catalent Pharma Solutions Limited
Swindon Company-level
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2024-05-30
Catalent Pharma Solutions, LLC
Saint Petersburg, Florida Company-level
Drug Quality Assurance Not posted No Action Indicated (NAI)
2024-05-24
Catalent Pharma Solutions LLC
Morrisville, North Carolina Facility-linked
Blood and Blood Products Yes Voluntary Action Indicated (VAI)
2024-01-31
Catalent Greenville Inc
Greenville, North Carolina Facility-linked
Drug Quality Assurance Not posted No Action Indicated (NAI)
2023-11-15
Catalent Indiana, LLC
Bloomington, Indiana Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2023-06-15
Catalent U.K. Swindon Zydis Limited
Swindon Company-level
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2023-03-10
Catalent Maryland Inc
Harmans, Maryland Facility-linked
Vaccines and Allergenic Products Not posted Voluntary Action Indicated (VAI)
2023-01-24
Catalent Maryland Inc
Harmans, Maryland Facility-linked
Human Cellular, Tissue, and Gene Therapies Not posted No Action Indicated (NAI)
2023-01-11
Catalent Pharma Solutions, LLC
Winchester, Kentucky Company-level
Drug Quality Assurance Yes Voluntary Action Indicated (VAI)
2022-12-15
Catalent Pharma Solutions LLC
Morrisville, North Carolina Facility-linked
Drug Quality Assurance Yes Voluntary Action Indicated (VAI)
2022-09-01
Catalent Indiana, LLC
Bloomington, Indiana Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2022-06-22
Catalent Micron Technologies, Limited
Dartford Company-level
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2022-03-04
Catalent CTS, LLC
Kansas City, Missouri Company-level
Drug Quality Assurance Not posted No Action Indicated (NAI)
2021-11-17
Catalent Maryland Inc
Harmans, Maryland Facility-linked
Vaccines and Allergenic Products Not posted Voluntary Action Indicated (VAI)
2026-01-30
Catalent Pharma Solutions, LLC
Saint Petersburg, Florida Company-level
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
Source: FDA Data Dashboard · Retrieved Nov 21, 2026

Catalent FDA 483 Findings 22 observations · 2022-12-15 → 2026-05-22 ?

By subsystem

  • Documentation & Records 8 (36.4%)
  • Equipment & Facilities 6 (27.3%)
  • Laboratory Controls 4 (18.2%)
  • Other 2 (9.1%)
  • Environmental Monitoring 1 (4.5%)
  • CAPA 1 (4.5%)

By severity

  • 4 — Serious: 1
  • 3 — Moderate: 5
  • 2 — Minor: 16
  • Repeat observations: 0

Most severe findings

  • Serious (4) Environmental Monitoring 2022-12-15 21 CFR 211.167(a)
    Sterility/pyrogens - test methods written, followed

    "Test procedures relative to appropriate laboratory testing for pyrogens are not written."

  • Moderate (3) Laboratory Controls 2025-10-24 21 CFR 211.166(a)
    Written program not followed

    "The written stability testing program is not followed."

  • Moderate (3) Laboratory Controls 2025-10-24 21 CFR 211.165(b)
    Microbiological testing

    "Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing."

Catalent EMA GMP Compliance 21 certificates

2026-05
2026-05
2026-04
2026-01
2026-01
2025-09
2024-05
2024-05
2024-04
2024-04
2024-03
2024-03
2024-03
2024-03
2024-03
2024-02
2024-02
2024-02
2020-01
2020-01
2020-01
Compliant Non-Compliant
Certificate Site Country Inspection Date Status
DE_BW_01_GMP_2026_0170 Catalent Germany Schorndorf GmbH Germany 2026-05-22 COMPLIANT
DE_BW_01_GMP_2026_0171 Catalent Germany Schorndorf GmbH Germany 2026-05-22 COMPLIANT
IT/110/H/2026 Catalent Anagni S.r.l. Italy 2026-04-15 COMPLIANT
2026_HPF_FR_061 Catalent France Limoges S.A.S. France 2026-01-16 COMPLIANT
2026_HPF_FR_060 Catalent France Limoges S.A.S. France 2026-01-16 COMPLIANT
DE_NW_03_GMP_2026_0037 Catalent Duesseldorf GmbH Germany 2025-09-11 COMPLIANT
BE/GMP/2024/061 Catalent Gosselies Belgium 2024-05-27 COMPLIANT
BE/GMP/2024/060 Catalent Gosselies Belgium 2024-05-27 COMPLIANT
DE_BW_01_GMP_2024_0147 Catalent Germany Schorndorf GmbH Germany 2024-04-12 COMPLIANT
DE_BW_01_GMP_2024_0177 Catalent Germany Schorndorf GmbH Germany 2024-04-12 COMPLIANT
IT/104/H/2024 Catalent Italy S.p.A. Italy 2024-03-22 COMPLIANT
IT/98/H/2026 Catalent Italy S.p.A. Italy 2024-03-22 COMPLIANT
IT/103/H/2026 Catalent Italy S.p.A. Italy 2024-03-22 COMPLIANT
BE/GMP/2024/022 Catalent Gosselies PS Belgium 2024-03-15 COMPLIANT
BE/GMP/2024/021 Catalent Gosselies PS Belgium 2024-03-15 COMPLIANT
IT/234/H/2024 Catalent Anagni S.r.l. Italy 2024-02-23 COMPLIANT
DE_BW_01_GMP_2024_0042 Catalent Germany Eberbach GmbH Germany 2024-02-02 COMPLIANT
DE_BW_01_GMP_2024_0040 Catalent Germany Eberbach GmbH Germany 2024-02-02 COMPLIANT
BE/GMP/2020/003 Catalent Belgium SA Belgium 2020-01-20 COMPLIANT
BE/GMP/2020/007 Catalent Belgium SA Belgium 2020-01-20 COMPLIANT
BE/GMP/2020/013 Catalent Belgium SA Belgium 2020-01-20 COMPLIANT
Source: EMA EudraGMDP · Retrieved Nov 21, 2026

Catalent MHRA GMP Compliance 18 certificates

2026-05
2026-05
2025-06
2025-06
2025-06
2024-10
2023-06
2022-06
2022-06
2021-03
2017-03
2017-03
2016-10
2015-10
2013-09
2013-02
2011-03
2009-02
Compliant Non-Compliant
Certificate Site City / Postcode Inspection Date Status
UK MIA 14023 Insp GMP/IMP 14023/4574-0025[H] CATALENT UK SWINDON ZYDIS LIMITED SWINDON SN5 8RU 2026-05-12 COMPLIANT
UK MIA(IMP) 14023 Insp GMP/IMP 14023/4574-0025[I] CATALENT UK SWINDON ZYDIS LIMITED SWINDON SN5 8RU 2026-05-12 COMPLIANT
UK MIA 5451 Insp GMP/IMP 5451/16389-0023[H] CATALENT MICRON TECHNOLOGIES LIMITED DARTFORD DA2 6QY 2025-06-26 COMPLIANT
UK MIA(IMP) 5451 Insp GMP/IMP 5451/16389-0023[I] CATALENT MICRON TECHNOLOGIES LIMITED DARTFORD DA2 6QY 2025-06-26 COMPLIANT
UK API 5451 Insp GMP/IMP 5451/16389-0023 CATALENT MICRON TECHNOLOGIES LIMITED DARTFORD DA2 6QY 2025-06-26 COMPLIANT
UK MIA 14023 Insp GMP 14023/4574-0024[H] CATALENT UK SWINDON ZYDIS LIMITED SWINDON SN5 8RU 2024-10-09 COMPLIANT
UK MIA(IMP) 14023 Insp GMP/IMP 14023/4574-0022[I] CATALENT UK SWINDON ZYDIS LIMITED SWINDON SN5 8RU 2023-06-13 COMPLIANT
UK MIA 5451 Insp GMP/IMP 5451/16389-0021[H] CATALENT MICRON TECHNOLOGIES LIMITED DARTFORD DA2 6QY 2022-06-21 COMPLIANT
UK ManA 5451 Insp GMP 5451/16389-0022[V] CATALENT MICRON TECHNOLOGIES LIMITED DARTFORD DA2 6QY 2022-06-21 COMPLIANT
UK MIA 32496 Insp GMP 5451/16389-0019[H] CATALENT MICRON TECHNOLOGIES LIMITED DARTFORD DA2 6QY 2021-03-29 COMPLIANT
UK GMP 20656 Insp GMP 33168/460035-0005[H] CATALENT PHARMA SOLUTIONS LLC 33716 2017-03-27 COMPLIANT
UK GMP 20657 Insp GMP 20657/873857-0004[H] CATALENT PHARMA SOLUTIONS LLC 40391 2017-03-13 COMPLIANT
UK GMP 20656 Insp GMP 20656/430174-0010[H] CATALENT PHARMA SOLUTIONS LLC NEW JERSEY 08873 2016-10-17 COMPLIANT
UK GMP 20656 Insp GMP 20656/430168-0005[H] CATALENT PHARMA SOLUTIONS INCORPORATED 19114 2015-10-05 COMPLIANT
UK GMP 20656 Insp GMP/IMP 20656/430174-0009 [V] CATALENT PHARMA SOLUTIONS LLC NEW JERSEY 08873 2013-09-17 COMPLIANT
UK GMP 20657 Insp GMP 27385/113084-0005[H] CATALENT PHARMA SOLUTIONS 64137 2013-02-25 COMPLIANT
UK API 18653 Insp GMP 18653/2970147-0002 CATALENT MICRON TECHNOLOGIES INCORPORATED 19355 2011-03-28 COMPLIANT
UK GMP 33624 Insp GMP 33624/542366-0001[H] CATALENT PHARMA SOLUTIONS PR-00791 2009-02-13 COMPLIANT
Source: MHRA GMDP Database · Retrieved Nov 21, 2026

Japan-accredited overseas site (PMDA)

biologics, cell and gene therapy (CGT), general (non-sterile), packaging/storage only, CGT packaging/storage only · 12 sites

  • Eberbach, Germany · Catalent Germany Eberbach GmbH — general (non-sterile) · valid to Dec 31, 2026 renewal filed
  • Schorndorf, Germany · Catalent Germany Schorndorf GmbH — general (non-sterile) · valid to Oct 30, 2031
  • Dartford, United Kingdom · Catalent Micron Technologies Ltd. — general (non-sterile) · valid to Jul 7, 2030
  • Swindon, United Kingdom · Catalent U.K. Swindon Zydis Limited — general (non-sterile) · valid to Mar 25, 2027 renewal due
  • Baltimore, United States · Catalent Maryland, Inc. — cell and gene therapy (CGT) · valid to Jul 22, 2029
  • Greenville, United States · Catalent Greenville, Inc. — general (non-sterile) · valid to Aug 28, 2028
  • Harmans, United States · Catalent Maryland, Inc. — cell and gene therapy (CGT) · valid to Jul 22, 2029
  • Kansas City, United States · Catalent CTS, LLC — general (non-sterile), packaging/storage only · valid to May 21, 2028
  • Malvern, United States · Catalent Micron Technologies, Inc. — general (non-sterile) · valid to Jul 7, 2030
  • Morrisville, United States · Catalent Pharma Solutions, LLC — general (non-sterile) · valid to Mar 20, 2029
  • Philadelphia, United States · Catalent Pharma Solutions — biologics, packaging/storage only, CGT packaging/storage only · valid to Jan 22, 2028
  • St. Petersburg, United States · Catalent Pharma Solutions, LLC — general (non-sterile) · valid to Sep 1, 2028
Previously accredited (cancelled) · 2
  • Schorndorf, Germany · Catalent Germany Schorndorf GmbH — general (non-sterile) · cancelled Feb 23, 2016
  • St. Petersburg, United States · Catalent Pharma Solutions, LLC — general (non-sterile) · cancelled Jan 23, 2013

No longer on PMDA's current list. Shown for history only; not used in search tags.

PMDA accreditation of a foreign manufacturing site is recognition within Japan's regulatory system, not an inspection outcome. PMDA's list covers only manufacturing sites outside Japan, so a company's plants in Japan are not on it. Source: PMDA, list of accredited/registered foreign manufacturers (as of Oct 16, 2026), Public Data License 1.0 (terms)

Hiring Activity 311 open roles Beta

From public job postings on Catalent's careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
311
open roles
225
in manufacturing, quality, PD/MSAT, engineering or regulatory (72%)
Trend from Nov 25, 2026
Tracking started Oct 26, 2026. 30-day change shows after 30 days, 90-day after Jan 24, 2027.
Since Nov 19, 2026: 16 new postings, 27 taken down.
What this may mean
  • 32 manufacturing and operations openings at Madison, Wisconsin, United States of America. That fits staffing of production shifts; on its own it doesn't show new capacity.
  • 8 manufacturing and operations openings at Greenville, North Carolina, United States of America. That fits staffing of production shifts; on its own it doesn't show new capacity.
  • 12 job titles mention mRNA (Madison, Wisconsin, United States of America). That points to mRNA work there as of Nov 20, 2026, not to its size or stage.
By function
Manufacturing & operations 97
Quality (QA / QC) 48
Process development & MSAT 43
Regulatory 2
Engineering & facilities 35
Commercial, BD & client projects 37
Other (finance, HR, IT, other) 49
By site · 310 of 311 postings give a location (100%)
Madison, Wisconsin, United States of America
32 mfg/ops · 13 QA/QC · 9 PD/MSAT · 6 eng. · 4 other
64
Harmans, Maryland, United States of America profile site
15 mfg/ops · 5 QA/QC · 3 PD/MSAT · 9 eng. · 2 other
34
Kansas City, Missouri, United States of America
3 mfg/ops · 5 QA/QC · 10 PD/MSAT · 4 eng. · 9 other
31
St. Petersburg, Florida, United States of America
8 mfg/ops · 2 QA/QC · 4 PD/MSAT · 4 other
18
Winchester, Kentucky, United States of America profile site
4 mfg/ops · 4 QA/QC · 2 PD/MSAT · 1 eng. · 5 other
16
Greenville, North Carolina, United States of America profile site
8 mfg/ops · 3 QA/QC · 2 PD/MSAT · 2 other
15
Swindon, Wiltshire, United Kingdom profile site
· 2 PD/MSAT · 7 eng. · 4 other
13
+ 27 more locations
No location in the feed1
Modality words in job titles
Biologics (cell culture, USP/DSP)24mRNA12Fill-finish / aseptic4Gene therapy3Plasmid DNA1
Notable roles
Director Global Supply Chain and Process Excellence Clinical Specialty Services Senior operations / quality role · Remote, Pennsylvania, United States...
Director Manufacturing Operations Senior operations / quality role · Kansas City, Missouri, United States...
Director Manufacturing Sciences and Technology Senior operations / quality role · Madison, Wisconsin, United States of America
Director of Engineering Facilities and Validation Senior operations / quality role · Harmans, Maryland, United States of America
Head of Planning Demand Management Senior operations / quality role · Eberbach, Baden-Wurttemberg, Germany
Latest postings
Technician - Biomanufacturing, Upstream (Nights) Manufacturing & operations · Madison, Wisconsin, United States of America · posted Nov 20, 2026
Specialist II - Materials Management Manufacturing & operations · Madison, Wisconsin, United States of America · posted Nov 20, 2026
Senior Associate - Biomanufacturing, Central Services Manufacturing & operations · Madison, Wisconsin, United States of America · posted Nov 20, 2026
Production Compliance Associate (12 month contract) Quality (QA / QC) · Windsor, Ontario, Canada · posted Nov 20, 2026
Manufacturing Associate II, Fill/Finish Manufacturing & operations · Harmans, Maryland, United States of America · posted Nov 20, 2026
Manufacturing Associate II, Fill/Finish Manufacturing & operations · Harmans, Maryland, United States of America · posted Nov 20, 2026
Lead Associate I - Biomanufacturing, Upstream Manufacturing & operations · Madison, Wisconsin, United States of America · posted Nov 20, 2026
Human Resources Director Other (finance, HR, IT, other) · Malvern, Pennsylvania, United States... · posted Nov 20, 2026
Associate - Biomanufacturing, Upstream (Nights) Manufacturing & operations · Madison, Wisconsin, United States of America · posted Nov 20, 2026
Supervisor - Biomanufacturing, Central Services Manufacturing & operations · Madison, Wisconsin, United States of America · posted Nov 19, 2026
Production Helper Manufacturing & operations · Indaiatuba, São Paulo, Brazil · posted Nov 19, 2026
Manufacturing Process Engineer - Biomanufacturing. CS/US Process development & MSAT · Madison, Wisconsin, United States of America · posted Nov 19, 2026
Coverage: counted from Catalent's own careers board. 1 of 311 postings (0%) have no location in the feed, so the site view is partial. Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source: careers.catalent.com · Checked Nov 20, 2026 · Tracking since Oct 26, 2026

Company Signals 20 articles

Company announcements, not verified evidence. They do not change any score.
general 2026-10-07
Catalent wins access to Iro and launches next-gen development platform - Fierce Pharma
Catalent wins access to Iro and launches next-gen development platform  Fierce Pharma
general 2026-10-06
Catalent launches ten-month gene-to-drug substance programme for complex biologics - Manufacturing Chemist
Catalent launches ten-month gene-to-drug substance programme for complex biologics  Manufacturing Chemist
partnership 2026-09-30
ALK, Catalent Expand Long-Term Contract Manufacturing Collaboration - Contract Pharma
ALK, Catalent Expand Long-Term Contract Manufacturing Collaboration  Contract Pharma
partnership 2026-04-30
Cartherics and Catalent Expand Commercial License Agreement - BioInformant
Cartherics and Catalent Expand Commercial License Agreement  BioInformant
partnership 2026-04-23
Cartherics and Catalent announce enhanced partnership - Lab + Life Scientist
Cartherics and Catalent announce enhanced partnership  Lab + Life Scientist
general 2026-04-19
Catalent Inc stock (US1488061029): Why Google Discover changes matter more now - AD HOC NEWS
Catalent Inc stock (US1488061029): Why Google Discover changes matter more now  AD HOC NEWS
general 2026-04-19
Catalent Inc stock (US1488061029): Why Google Discover changes matter more now - AD HOC NEWS
Catalent Inc stock (US1488061029): Why Google Discover changes matter more now  AD HOC NEWS
general 2026-04-19
Catalent Inc stock (US1488061029): Why Google Discover changes matter more now - AD HOC NEWS
Catalent Inc stock (US1488061029): Why Google Discover changes matter more now  AD HOC NEWS
partnership 2026-04-14
Cartherics and Catalent deepen partnership to accelerate next generation cell therapies - Biotech Dispatch
Cartherics and Catalent deepen partnership to accelerate next generation cell therapies  Biotech Dispatch
partnership 2026-04-13
Cartherics and Catalent expand commercial license agreement - Med-Tech Insights
Cartherics and Catalent expand commercial license agreement  Med-Tech Insights
general 2026-04-11
Australia's Cartherics expands agreement with Catalent to focus on cancer and endometriosis treatment - BioSpectrum Asia
Australia's Cartherics expands agreement with Catalent to focus on cancer and endometriosis treatment  BioSpectrum Asia
general 2026-04-10
Cartherics deepens Catalent alliance to scale CAR-NK manufacturing - The Pharma Letter
Cartherics deepens Catalent alliance to scale CAR-NK manufacturing  The Pharma Letter
partnership 2026-04-10
Cartherics and Catalent Expand Commercial License Agreement - BioSpace
Cartherics and Catalent Expand Commercial License Agreement  BioSpace
partnership 2026-04-10
Cartherics and Catalent deepen partnership to accelerate next generation cell therapies - PharmaDispatch
Cartherics and Catalent deepen partnership to accelerate next generation cell therapies  PharmaDispatch
general 2026-04-10
Cartherics deepens Catalent alliance to scale CAR-NK manufacturing - The Pharma Letter
Cartherics deepens Catalent alliance to scale CAR-NK manufacturing  The Pharma Letter
partnership 2026-04-09
Cartherics and Catalent Expand Commercial License Agreement - Business Wire
Cartherics and Catalent Expand Commercial License Agreement  Business Wire
partnership 2026-04-09
Cartherics, Catalent Expand Partnership - Contract Pharma
Cartherics, Catalent Expand Partnership  Contract Pharma
partnership 2026-04-09
Cartherics and Catalent Expand Commercial License Agreement - PharmiWeb.com
Cartherics and Catalent Expand Commercial License Agreement  PharmiWeb.com
partnership 2026-04-01
Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases - BioInformant
Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases  BioInformant
general 2026-04-01
Layoffs at Novo’s Ex-Catalent Site Despite Signs of Turnaround, Continued Investment - BioSpace
Layoffs at Novo’s Ex-Catalent Site Despite Signs of Turnaround, Continued Investment  BioSpace

Frequently Asked Questions About Catalent

How many FDA inspections does Catalent have on record?
CDMO Signal tracks 25 FDA inspections for Catalent, sourced from the FDA inspection database. See the full inspection history above.
Has Catalent received an FDA warning letter?
Yes — CDMO Signal has 1 FDA warning letter on record for Catalent.
Does Catalent hold EMA or MHRA GMP certificates?
CDMO Signal tracks 21 EMA and 18 MHRA GMP certificates for Catalent.
What is Catalent's CDMO Signal Score?
Catalent has a Signal Score of 76/100, based on quality, operations, financial stability, and capacity data.
Evaluating Catalent for a manufacturing program?
Use the free AI matchmaker to compare Catalent against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Recombinant Protein CDMOs → ADC CDMOs → AAV CDMOs → mRNA CDMOs → Plasmid DNA CDMOs →

Similar CDMOs

Lonza
Basel, Switzerland
Signal Score: 72.8
AAV, Lentiviral, Cell Therapy, mRNA, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation, Small Molecule API, High-Potency APIs, Oral Solid Dose
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 79.9
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation
Samsung Biologics
Incheon, South Korea, Rockville, Maryland, USA
Signal Score: 61.5
Monoclonal Antibody, Recombinant Protein, ADC, mRNA, Bispecific Antibody, Antibody Conjugate
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Signal Score: 86.7
AAV, mRNA/LNP, Biologics, mRNA, Microbial Fermentation, Recombinant Protein
KBI Biopharma
Durham, NC · Boulder, CO
Signal Score: 84.1
Monoclonal Antibody, Recombinant Protein, AAV (analytical only), Plasmid DNA

Compare Catalent with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Catalent
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.